Contact this trialFirst, we need to learn more about you.
Radiopharmaceutical
Lu-177 Ludotadipep for Prostate Cancer
Recruiting2 awardsPhase 1 & 2
Los Angeles, California
This trial tests the safety and effectiveness of a radioactive drug called [177Lu]Ludotadipep. The drug works by delivering radiation directly to certain cells to treat the condition. Lutetium-177 (177Lu) has been widely used in targeted therapy, particularly in peptide receptor radionuclide therapy (PRRT) for treating neuroendocrine tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service